All 37 inherited annotation contexts were assessed through 19 database, seven binding and eleven functional decisions. The source records, their order, three curated natural splice-product objects and zero-quotation regime remain exact. The integrated review has one protein–membrane adaptor core; no new annotation or experimental proposal was added. Four legitimate generic binding observations remain non-core under the project exception, so the review status is DRAFT. The negated coated-vesicle context (index 24) remains an explicitly completed UNDECIDED assessment.
The 2010 Science paper has verified Expression of Concern and Erratum records, but the notice bodies and affected-panel/resolution scope remain unavailable. The original source is not declared retracted or misattributed. Independent 2012 and 2020 human FCHO1 evidence supports positive membrane, coat and endocytosis functions while preserving cell/cargo context. The 2020 Author Correction was read: it corrects the Discussion’s account of prior work and transferrin-receptor context, and does not state a figure or experimental-data correction. Original source caches remain unchanged.
The genuine Falcon attempt failed with HTTP 403 authentication failure; its perplexity-lite fallback failed with HTTP 401/insufficient_quota. Neither produced a provider report, and none was fabricated. Assessment instead uses the recorded original, database and supplement evidence. Raw provider traces are private and are not delivered.
The source guide records the combined access limits. The database journal, binding journal and functional journal retain their original bytes as historical stage records; their references to unfinished lane work do not describe the now-integrated annotation set. Source tables retain exact full-annotation/index joins. The normal-source closure retains all 26 accepted intake files plus four genuine additions; the already-present 2020 correction normal is selected from the original intake.
The final focused validation passes with five advisories: four permitted generic-binding rows and the standalone adaptor core not appearing as an existing annotation term. The core is supported by the accepted source synthesis; no new annotation row was added solely to silence that advisory. Computed status remains DRAFT.
Read the full formal and finished companion feedback for PR 5587 at head 1df5820455b092be40a8206935533b4d0b762b37. All 37 imported source objects/actions, three natural splice products and immutable caches remain unchanged. The proposal appends one IC protein-membrane adaptor annotation and the complete Calzoni 2019 reference (PMID:30822429), giving 38 annotation rows and 25 references. No new process or quotation is added.
The actual Calzoni main letter contributes human functional evidence: pre-transplant patient P2 cells showed reduced activation-induced proliferation and survival, and activated blasts showed impaired transferrin uptake with preserved TCR/CD3 internalization. These observations strengthen the two non-core T-cell contexts without treating the patient study as a repeat of the 2020 Jurkat TCR phenotype. The 2020 correction’s removal of the contrary Discussion claim is retained. Precise locators and limits are in the functional source guide.
Human FCHO1 lipid association, linker AP-2 interaction and muHD EPS15/intersectin interaction have experimental domain-localization and coat-recruitment support in PMID:22484487 and PMID:32098969. The added GO:0043495 IC row expresses this molecular bridge; official typed ancestry confirms that it is not an ancestor or descendant of the existing/replacement binding terms. The patient phenotype alone is not its evidence.
PTK6 binding refinements describe the identity of a measured interaction partner, not kinase activity or regulation. The 2019 Y2H work is related retesting, not independent orthogonal confirmation; no FCHO1-specific PCA evidence is claimed. The supported LGALS14/EXOSC5 pairs remain non-core under the user’s ClinGen curation instructions, which also prohibit adding publication quotations. The reviewer’s contrary policy premise does not override these explicit instructions.
UniProt’s clathrin/ITSN statements were considered with their mixed by-similarity/2012 provenance. Actual human intersectin association is reported in 2012, while its isolated-linker negative clathrin result does not refute every whole-protein association. The mature-vesicle NOT remains unresolved: UniProt repeats affirmative curated support with overlapping 2010 provenance, while the combined blot and antibody scope remain limiting. The 2010 notices are neither assumed retraction nor resolved concern. See the feedback decisions for exact source joins.